Moreover, ESS2 expression was highly correlated with adenosine deaminase acting on RNA (ADAR), IFN-inducible transmembrane protein (IFITM) 2, and IFITM3 in patients with prostate cancer (Fig. 3c). Here, ESS2 is linked to prostate carcinoma.